A provider briefing on Bromfenac availability in 2026: supply chain status, prescribing implications, alternatives, and tools to help your patients.
If your patients are reporting difficulty filling Bromfenac prescriptions, you're hearing a real and growing concern. While Bromfenac is not listed on formal shortage databases, the practical reality at the pharmacy counter tells a different story — especially for patients at chain pharmacies without established ophthalmic inventory.
This briefing covers the current supply landscape, prescribing considerations, cost and access barriers your patients face, and tools that can streamline the process for your practice.
Bromfenac's supply history is one of progressive brand attrition:
The result is a market where the active formulations are spread across a small number of manufacturers, and the most affordable option (generic 0.09%) has limited production capacity.
When writing for Bromfenac in 2026, consider these practical factors:
Not all Bromfenac products are interchangeable at the pharmacy level:
If you prescribe "bromfenac" without specifying a brand, the pharmacy will default to generic 0.09%. If you specifically need Prolensa or BromSite formulations, use DAW codes accordingly and be aware that prior authorization is more commonly required.
Many commercial and Medicare Part D plans have shifted ophthalmic NSAIDs to prior authorization or step therapy protocols. Common step therapy requirements include trial of generic ketorolac 0.5% before approving bromfenac. Plan ahead by:
As of early 2026:
The core issue is not manufacturing failure but distribution and stocking patterns. Pharmacies that don't regularly fill ophthalmic surgical prescriptions may not maintain inventory.
Patient-facing pricing as of 2026:
For uninsured or underinsured patients, NeedyMeds and RxAssist list patient assistance resources. Sun Pharma and Bausch + Lomb have manufacturer assistance programs for qualifying patients.
Direct patients to our patient savings guide for step-by-step instructions on reducing out-of-pocket costs.
Medfinder offers real-time pharmacy stock checking that your staff can use to verify Bromfenac availability before the patient leaves your office. By directing patients to a pharmacy that has stock on hand, you reduce callback volume and improve the post-operative experience.
Consider adding these steps to your pre-surgical checklist:
When Bromfenac is unavailable, evidence-based alternatives include:
For a patient-facing comparison, refer patients to: Alternatives to Bromfenac.
Several trends may improve Bromfenac access in the coming years:
Bromfenac remains a valuable tool in post-cataract care, but its practical availability requires proactive management from the prescriber side. By planning prescriptions ahead of surgery, maintaining familiarity with alternatives, and leveraging stock-checking tools, you can ensure your patients get the post-operative care they need without unnecessary delays.
For additional provider resources, visit Medfinder for Providers. For guidance on helping patients navigate cost barriers, see our provider's guide to helping patients save money on Bromfenac.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
